127 related articles for article (PubMed ID: 31432749)
1. EF2-kinase targeted cobalt-ferrite siRNA-nanotherapy suppresses
Asik E; Akpinar Y; Caner A; Kahraman N; Guray T; Volkan M; Albarracin C; Pataer A; Arun B; Ozpolat B
Nanomedicine (Lond); 2019 Sep; 14(17):2315-2338. PubMed ID: 31432749
[No Abstract] [Full Text] [Related]
2. Targeting eukaryotic elongation factor-2 kinase suppresses the growth and peritoneal metastasis of ovarian cancer.
Erdogan MA; Ashour A; Yuca E; Gorgulu K; Ozpolat B
Cell Signal; 2021 May; 81():109938. PubMed ID: 33539938
[TBL] [Abstract][Full Text] [Related]
3. FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells.
Hamurcu Z; Ashour A; Kahraman N; Ozpolat B
Oncotarget; 2016 Mar; 7(13):16619-35. PubMed ID: 26918606
[TBL] [Abstract][Full Text] [Related]
4. Assessment of In Vivo siRNA Delivery in Cancer Mouse Models.
Hatakeyama H; Wu SY; Mangala LS; Lopez-Berestein G; Sood AK
Methods Mol Biol; 2016; 1402():189-197. PubMed ID: 26721492
[TBL] [Abstract][Full Text] [Related]
5. Glucose-linked sub-50-nm unimer polyion complex-assembled gold nanoparticles for targeted siRNA delivery to glucose transporter 1-overexpressing breast cancer stem-like cells.
Yi Y; Kim HJ; Zheng M; Mi P; Naito M; Kim BS; Min HS; Hayashi K; Perche F; Toh K; Liu X; Mochida Y; Kinoh H; Cabral H; Miyata K; Kataoka K
J Control Release; 2019 Feb; 295():268-277. PubMed ID: 30639386
[TBL] [Abstract][Full Text] [Related]
6. Effect of siRNA pre-Exposure on Subsequent Response to siRNA Therapy.
Aliabadi HM; Mahdipoor P; Kucharsky C; Chan N; Uludağ H
Pharm Res; 2015 Dec; 32(12):3813-26. PubMed ID: 26129766
[TBL] [Abstract][Full Text] [Related]
7. Combination antitumor immunotherapy with VEGF and PIGF siRNA via systemic delivery of multi-functionalized nanoparticles to tumor-associated macrophages and breast cancer cells.
Song Y; Tang C; Yin C
Biomaterials; 2018 Dec; 185():117-132. PubMed ID: 30241030
[TBL] [Abstract][Full Text] [Related]
8. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.
Varshosaz J; Farzan M
World J Gastroenterol; 2015 Nov; 21(42):12022-41. PubMed ID: 26576089
[TBL] [Abstract][Full Text] [Related]
9. Elongation factor-2 kinase (eEF-2K) expression is associated with poor patient survival and promotes proliferation, invasion and tumor growth of lung cancer.
Bircan HA; Gurbuz N; Pataer A; Caner A; Kahraman N; Bayraktar E; Bayraktar R; Erdogan MA; Kabil N; Ozpolat B
Lung Cancer; 2018 Oct; 124():31-39. PubMed ID: 30268477
[TBL] [Abstract][Full Text] [Related]
10. Glucose-regulated protein 78 as a novel effector of BRCA1 for inhibiting stress-induced apoptosis.
Yeung BH; Kwan BW; He QY; Lee AS; Liu J; Wong AS
Oncogene; 2008 Dec; 27(53):6782-9. PubMed ID: 18776923
[TBL] [Abstract][Full Text] [Related]
11. One-pot synthesis of pH-responsive hybrid nanogel particles for the intracellular delivery of small interfering RNA.
Khaled SZ; Cevenini A; Yazdi IK; Parodi A; Evangelopoulos M; Corbo C; Scaria S; Hu Y; Haddix SG; Corradetti B; Salvatore F; Tasciotti E
Biomaterials; 2016 May; 87():57-68. PubMed ID: 26901429
[TBL] [Abstract][Full Text] [Related]
12. Modified gold-based siRNA nanotherapeutics for targeted therapy of triple-negative breast cancer.
Shahbazi R; Asik E; Kahraman N; Turk M; Ozpolat B; Ulubayram K
Nanomedicine (Lond); 2017 Aug; 12(16):1961-1973. PubMed ID: 28745127
[TBL] [Abstract][Full Text] [Related]
13. Co-delivery of VEGF and Bcl-2 dual-targeted siRNA polymer using a single nanoparticle for synergistic anti-cancer effects in vivo.
Lee SJ; Yook S; Yhee JY; Yoon HY; Kim MG; Ku SH; Kim SH; Park JH; Jeong JH; Kwon IC; Lee S; Lee H; Kim K
J Control Release; 2015 Dec; 220(Pt B):631-41. PubMed ID: 26307351
[TBL] [Abstract][Full Text] [Related]
14. CD73 specific siRNA loaded chitosan lactate nanoparticles potentiate the antitumor effect of a dendritic cell vaccine in 4T1 breast cancer bearing mice.
Jadidi-Niaragh F; Atyabi F; Rastegari A; Kheshtchin N; Arab S; Hassannia H; Ajami M; Mirsanei Z; Habibi S; Masoumi F; Noorbakhsh F; Shokri F; Hadjati J
J Control Release; 2017 Jan; 246():46-59. PubMed ID: 27993599
[TBL] [Abstract][Full Text] [Related]
15. Effects of targeted nano-delivery systems combined with hTERT-siRNA and Bmi-1-siRNA on MCF-7 cells.
Liu L; Li H; Zhang M; Lv X
Int J Clin Exp Pathol; 2015; 8(6):6674-82. PubMed ID: 26261549
[TBL] [Abstract][Full Text] [Related]
16. Lipidation of polyethylenimine-based polyplex increases serum stability of bioengineered RNAi agents and offers more consistent tumoral gene knockdown in vivo.
Zhang QY; Ho PY; Tu MJ; Jilek JL; Chen QX; Zeng S; Yu AM
Int J Pharm; 2018 Aug; 547(1-2):537-544. PubMed ID: 29894758
[TBL] [Abstract][Full Text] [Related]
17. Reversibly Stabilized Polycation Nanoparticles for Combination Treatment of Early- and Late-Stage Metastatic Breast Cancer.
Chen G; Wang Y; Wu P; Zhou Y; Yu F; Zhu C; Li Z; Hang Y; Wang K; Li J; Sun M; Oupicky D
ACS Nano; 2018 Jul; 12(7):6620-6636. PubMed ID: 29985577
[TBL] [Abstract][Full Text] [Related]
18. Captopril-polyethyleneimine conjugate modified gold nanoparticles for co-delivery of drug and gene in anti-angiogenesis breast cancer therapy.
Li M; Li Y; Huang X; Lu X
J Biomater Sci Polym Ed; 2015; 26(13):813-27. PubMed ID: 26166244
[TBL] [Abstract][Full Text] [Related]
19. Polo-like Kinase 1-targeting Chitosan Nanoparticles Suppress the Progression of Hepatocellular Carcinoma.
Wang D; Chang R; Wang G; Hu B; Qiang Y; Chen Z
Anticancer Agents Med Chem; 2017; 17(7):948-954. PubMed ID: 27671301
[TBL] [Abstract][Full Text] [Related]
20. Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1.
Zhu Y; Liu Y; Zhang C; Chu J; Wu Y; Li Y; Liu J; Li Q; Li S; Shi Q; Jin L; Zhao J; Yin D; Efroni S; Su F; Yao H; Song E; Liu Q
Nat Commun; 2018 Apr; 9(1):1595. PubMed ID: 29686231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]